Targeted Oncology· @TargetedOnc · X·· 15 hours agoScore70
Body · original
Impressive Phase III INTerpath-001 data at #ESMO26!
Personalized mRNA vaccine + pembrolizumab in resected melanoma:
2-year RFS: 82.2% vs 70% (HR 0.58)
DMFS: 88.5% vs 80.2% (HR 0.62)
An important advance. Will this translate into more cures?
115 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com